Global Epigenetics Diagnostic Market is Growing with a CAGR of 15.2% in the Forecast Period of 2021 to 2028

Global Epigenetics Diagnostic Market is growing with factors such as rising prevalence of cancer, growing geriatric population, increasing R&D associated with epigenetics for the novel product launch along with government support, rising collaborations among key market players among others. The large number of market players is also propelling the demand of the market.

Technological advancements have propelled the demand of the market. However, the high cost of epigenetics diagnostic equipment may impact the demand of the market.

Global Epigenetics Diagnostic Market Scenario                        

According to Data Bridge Market Research, the market for global epigenetics diagnostic in North America has the highest market share, followed by Europe and Asia-Pacific. Market leader is Illumina, Inc., which accounts an estimated market share of approximately 11.10% in the global market. The company has gained outstanding sale by providing novel technology based epigenetics equipment.

  • In January 2020, Illumina, Inc. introduced the NovaSeq Series. This announcement has strengthened company’s footprint in market.

Epigenetics Diagnostic MarketTrends Impacting the Market

Now the question is which other regions Illumina, Inc., Thermo Fisher Scientific, Inc. & Merck KGaA are targeting? Data Bridge Market Research has forecasted a large growth in North America epigenetics diagnostic market and the market leaders targeting U.S. and Canada to be their next pocket revenue for 2021.

The epigenetics diagnostic market is becoming more competitive with companies Illumina, Inc., Thermo Fisher Scientific, Inc. & Merck KGaA. These are the top dominating companies in epigenetics diagnostic market and have launched novel epigenetics diagnostic products in the market. The data bridge market research new reports highlight the major growth factors and opportunities in the global epigenetics diagnostic market.

For more analysis on the global epigenetics diagnostic market request for a briefing with our analysts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-epigenetics-diagnostic-market

Global Epigenetics Diagnostic Market Developments

  • In August 2021, Merck KGaA has acquired privately held OncoEthix, which is developing a class of epigenetics-based compounds. This acquisition has boosted revenue growth of the company.
  • In August 2021, F. Hoffmann-La Roche Ltd received FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy. Approval provides clinicians with access to a fully automated panel of MMR biomarkers tested by immunohistochemistry (IHC), enabling impactful treatment decisions for patients. This helped the company to expand its product portfolio as well as enhance revenue.

Scope of the Epigenetics Diagnostic Market

Global epigenetics diagnostic market is segmented on the basis of countries into the U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Switzerland, Russia, Netherlands, Belgium, Ireland, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Philippines, Indonesia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt and Rest of Middle East and Africa. All country based analysis of the global epigenetics diagnostic market is further analysed based on maximum granularity into further segmentation.

  • On the basis of product, the global epigenetics diagnostic market is segmented into reagents, kits, instruments & consumables, bioinformatics tools, and enzymes. On the basis of technology, the global epigenetics diagnostic market is segmented into DNA methylation, histone methylation, chromatin structures, histone acetylation, large non-coding RNA, and microRNA modification. On the basis of type of therapy, the global epigenetics diagnostic market is segmented into histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) inhibitors, and others. On the basis of application, the global epigenetics diagnostic market is segmented into oncology, cardiovascular diseases, metabolic diseases, immunology, inflammatory diseases, and others. On the basis of end user, the global epigenetics diagnostic market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others. On the basis of distribution channel, the global epigenetics diagnostic market is segmented into direct tender and retail sales.

To know more about the study https://www.databridgemarketresearch.com/reports/global-epigenetics-diagnostic-market

Key Pointers Covered in Epigenetics Diagnostic Market Industry Trends and Forecast to 2028

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries
  • Market value and over view of epigenetics diagnostic market
  • Company profiling of top eight players of epigenetics diagnostic market

Key Market Competitors Covered in the Report

  • Zymo Research Corporation
  • PerkinElmer Inc.
  • Diagenode
  • F. Hoffman-La Roche Ltd
  • EPICYPHER
  • Cambridge Epigenetix (CEGX)
  • Promega Corporation
  • QIAGEN
  • Pacific Biosciences of California, Inc.
  • Epigenomics AG
  • Mnemo
  • Reaction Biology
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Merck KGaA
  •  Illumina, Inc.
  • ACTIVEMOTIF
  • New England Biolabs
  • Thermo Fisher Scientific, Inc.
  • EpiGentek Group Inc.
  • Enzo Life Sciences, Inc.
  • Epizyme, Inc.
  • GlaxoSmithKline plc.
  • Eclipse BioInnovations
  • MDxHealth
  • Abcam plc
  • Salarius Pharmaceuticals, Inc.
  • Datar Cancer Genetics
  • Bluestar Genomics Inc.

Above are the key players covered in the report, to know about more and exhaustive list of epigenetics diagnostic companies’, contact us https://www.databridgemarketresearch.com/toc/?dbmr=global-epigenetics-diagnostic-market

Research Methodology: Global Epigenetics Diagnostic Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Manufacturer, Geneticists, Healthcare Industry, Scientists, Research Laboratories
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Related Reports

Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/